Sarah Gonzales Zoeteman
Family · Oak Lawn, ILNPI 1508351446
Payments from drug & device makers
Across 116 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$694
- Novo Nordisk$348
- Pfizer$227
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$147
- AstraZeneca$132
- Exact Sciences$122
- plus $693 from 15 others
What the payments were for
- Food & beverage$2,362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 34 | $694 |
| Novo Nordisk | 17 | $348 |
| Pfizer | 12 | $227 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $147 |
| AstraZeneca | 7 | $132 |
| Exact Sciences | 5 | $122 |
| AbbVie | 5 | $103 |
| Abbott | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 3 | $64 |
| Biohaven Pharmaceuticals, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $57 |
| Shield Therapeutics Inc | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Novartis | 2 | $45 |
| GSK | 2 | $38 |
| Genentech USA, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Amgen | 1 | $20 |
How this compares
$2,362 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 36 | $56,101 |
| EliquisApixaban | 27 | $38,164 |
| OzempicSemaglutide | 24 | $35,639 |
| RybelsusSemaglutide | 14 | $32,243 |
| LinzessLinaclotide | 15 | $19,430 |
| FarxigaDapagliflozin Propanediol | 20 | $18,920 |
| TrulicityDulaglutide | 11 | $18,276 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $6,831 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $4,754 |
| Atorvastatin Calcium | 231 | $2,310 |
| Allopurinol | 39 | $1,926 |
| Metoprolol Succinate | 131 | $1,814 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,784 |
| Amlodipine Besylate | 202 | $1,552 |
| Ventolin HfaAlbuterol Sulfate | 12 | $1,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $694 | $74,37747 claims |
| Novo NordiskOzempic, Rybelsus | $348 | $67,88238 claims |
| PfizerEliquis | $227 | $38,16427 claims |
| AbbVieLinzess | $103 | $19,43015 claims |
| AstraZenecaFarxiga | $132 | $18,92020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.
Other family in Oak Lawn
- Barbara KowalczykOak Lawn$74K
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.